Abstract: The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.
Type:
Grant
Filed:
February 2, 2018
Date of Patent:
July 4, 2023
Assignees:
Acticor Biotech, Université Paris Cité, Université Paris-XIII, Inserm (Institut National de la Santé et de la Recherche
Médicale), Université Paris-Saclay
Inventors:
Philippe Billiald, Martine Jandrot-Perrus, Gilles Avenard
Abstract: The present invention relates to humanized anti-human GPVI antibodies and uses thereof.
Type:
Grant
Filed:
August 5, 2016
Date of Patent:
November 24, 2020
Assignees:
ACTICOR BIOTECH, UNIVERSITE DE PARIS, UNIVERSITÉ PARIS-XIII, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE PARIS-SACLAY
Inventors:
Philippe Billiald, Martine Jandrot-Perrus
Abstract: The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.
Type:
Application
Filed:
February 2, 2018
Publication date:
December 5, 2019
Applicants:
Acticor Biotech, Université Paris Diderot - Paris 7, Université Paris-XIII, Nserm (Institut National de la Santé et de la Recherche Médicale), Université Paris-Sud 11
Inventors:
Philippe BILLIALD, Martine JANDROT-PERRUS, Gilles AVENARD